DLA Piper assisted Curasight with global license of uTRACE® for use in prostate cancer

Danish Curasight A/S has entered into an exclusive global license and collaboration agreement with Curium Inc. for the development and commercialization of uTRACE® for use in prostate cancer.

Curasight will develop its proprietary uTRACE® technology for use in prostate cancer until regulatory approval is granted in the EU and USA. Curium will have responsibility for the commercial manufacture of uTRACE® and world-wide commercialization.

Curasight is eligible to receive up to USD 70 mn in development and commercial milestones as well as double-digit percentage royalties on sales in major markets upon eventual commercialization.

In the company’s press release, CEO in Curasight, Ulrich Krasilnikoff, says: “This partnership supports further development of our diagnostic platform, bringing us closer to fulfilling our ambition of helping a large number of prostate cancer patients.”

Read more about the agreement here.

The DLA Piper team consisted of Ulrik Bangsbo Hansen, Partner and Head of the Life Science Sector Group in DLA Piper Denmark, Kate Black, Senior Associate, and Richard Taylor, Partner and Life Sciences lead for the UK and International Commercial Contracts.